Navigation Links
Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
Date:11/12/2013

o discuss the third quarter 2013 financial results and recent business highlights. The live call may be accessed by phone by calling (888) 895-5479 (domestic) or (847) 619‐6250 (international), participant code 36014873. The webcast can be accessed live on the Investor Relations section of the Orexigen web site at http://www.orexigen.com, and will be archived for 14 days following the call.

About Orexigen Therapeutics Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase 3 clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic, has completed Phase 2 clinical trials. Further information about the Company can be found at www.orexigen.com.

Forward‐Looking Statements Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward‐looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "should," "intends," "potential," "suggests," "assuming," "designed" and similar expressions are intended to identify forward‐looking statements. These statements are based on the Company's current beliefs and expectations. These forward‐looking statements include statements regarding: projected change in 2013 cash, cash equivalents, and marketable securities and expected year-end cash, cash equivalents, and marketable securities balance; the potential for, and timing of, the approval of a Contrave Marketing Authorization Application (MAA) in the European Union (EU); the probability of the interim analysi
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
2. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
3. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
4. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
5. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
6. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
7. Orexigen Therapeutics to Host Second Quarter 2013 Financial Results Conference Call and Webcast
8. Orexigen Therapeutics Announces Upcoming Clinical Data Presentations at American Diabetes Association Annual Scientific Meeting
9. Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference
10. Orexigen Therapeutics to Present at the UBS Global Healthcare Conference
11. Orexigen Therapeutics Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015  Pharmaceutical ... new drugs and tests, and this is ... instruments that can assist them. This according to ... Information said instruments such as mass spectrometry, ... in the identification of drug targets and ...
(Date:5/28/2015)...  IRIDEX Corporation (NASDAQ: IRIX ) today announced that ... Mackaness is scheduled to present at the LD Micro ... in Los Angeles . A ... the Event Calendar of the Investors section of IRIDEX,s website ... be available shortly after the conclusion of the presentation and ...
(Date:5/28/2015)... DUBLIN , May 28, 2015 ... has announced the addition of the "United ... report to their offering.      ... medical adhesives in the United States ... through 2020 Medical device manufacturers ...
Breaking Medicine Technology:Report: Proteomics Research Market Reaches $1.6 Billion 2Report: Proteomics Research Market Reaches $1.6 Billion 3United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3
... Minn., April 16, 2008 A new Mayo,Clinic ... protect against,mild cognitive impairment, a disorder of the ... This study will be presented at the,American Academy ... 16., Individuals with mild cognitive impairment can ...
... Support Moving Forward with a planned IND Filing for Novavax,s ... Seasonal Influenza Vaccine ... NVAX ) said today that it has received positive results ... influenza vaccine candidate. These findings will enable Novavax to,complete its ...
Cached Medicine Technology:Mayo Clinic Finds Exercise Can Reduce the Risk of Mild Cognitive Impairment 2Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate 2Novavax Reports Positive Results from Preclinical Studies of its VLP-based Trivalent Seasonal Influenza Vaccine Candidate 3
(Date:5/29/2015)... 29, 2015 Wimbledon Health Partners, the ... (EKG), echocardiogram and NCV testing, is proud to ... for EKG interpretation of athletes. , ... death during athletic activity. New findings presented in February ... to improve cardiac safety in athletes. Physiologic adaptations in ...
(Date:5/29/2015)... 29, 2015 Thursday, May 21st was the ... from all walks of life came together to raise money ... Day is a campaign dedicated to raising money for children ... and making people laugh, the people at Hands-On Seminars decided ... Here they provided food, fun and laughter to their ...
(Date:5/29/2015)... 2015 Belviq for weight loss ... prescription diet medication. In 2012, the FDA approved ... have a BMI >30. It is also approved ... one additional weight-related health condition such as high blood ... main function for weight loss focuses on the brain’s ...
(Date:5/28/2015)... External Counterpulsation (EECP/ECP) has been used ... United States. There are a growing number of people ... symptoms of angina and these patients are often times ... surgery. , “No option” patients are a sizable cohort ... that is considered unacceptable for heart stent or bypass. ...
(Date:5/28/2015)... May 28, 2015 AMVETS National Executive ... the Commission on Care established by Congress to examine ... veterans. , Appointed to the commission by Mitch McConnell, ... be one of only 15 voting members on the ... and Accountability Act of 2014. The goal of the ...
Breaking Medicine News(10 mins):Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 2Health News:Wimbledon Health Partners Incorporates Updated ‘Seattle Criteria’ for EKG Interpretation of Athletes 3Health News:Groups, such as Hands-On Physical Therapy, Across the Country, Host Their Own Events and Make the Inaugural Red Nose Day a Huge Success 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 3Health News:External Counterpulsation (EECP/ECP) a New Heart Disease Therapy Helps People of Calgary with Unstable Angina 2Health News:AMVETS Executive Director Stewart Hickey Appointed to Congressional Commission on Care 2
... ... TV 4 recently awarded Dr. Michael Macdonald of the Aesthetic Surgery Center ... awards. Dr. Macdonald is one of the few cosmetic surgeons in the ... and Reconstructive Surgery and Head and Neck Surgery. ,With over 20 years ...
... ... of successes in its Wide Format Digital Printing and ID Badge divisions. , ... Memphis, TN (PRWEB) April ... despite the tough economy. The company’s two distinct product divisions, Wide Format Digital Printing ...
... ... 2010 targets in the fight against the disease, World Vision’s End Malaria campaign is leading ... to press American congressional leaders to keep investing in programs that are saving the lives ... ...
... ... rash-inducing plants are growing faster and producing more potent toxins as compared ... create ideal conditions for these poisonous plants, producing larger and faster growth ... plants, the topical reactions become worse and affect a larger population, but ...
... ... or associated risk factors, today introduced ,How Your Brain Can Save Your Heart (And ... has shown to be critical for making permanent lifestyle changes that increase our prospects ... ...
... ... and American Society of Pain Educators to pursue publishing and teaching opportunities. , ... (PRWEB) April 16, 2010 ... management education and producers of PAINWeek ( www.painweek.org ) — the national ...
Cached Medicine News:Health News:Dr. Michael Macdonald Named Best Plastic Surgeon in San Francisco Bay Area 2Health News:Dr. Michael Macdonald Named Best Plastic Surgeon in San Francisco Bay Area 3Health News:LSI Earns 3M Warranty Certification; Gains Federal ID Badge Contracts 2Health News:LSI Earns 3M Warranty Certification; Gains Federal ID Badge Contracts 3Health News:World Vision Malaria Experts Available for Comment as World Malaria Day Approaches April 25 2Health News:World Vision Malaria Experts Available for Comment as World Malaria Day Approaches April 25 3Health News:Global Warming Increases The Potency Of Poison Ivy and Natural Antidotes 2Health News:Global Warming Increases The Potency Of Poison Ivy and Natural Antidotes 3Health News:Global Warming Increases The Potency Of Poison Ivy and Natural Antidotes 4Health News:HeartCoaches Introduces Brain-Based Strategies for a Healthy Heart 2Health News:HeartCoaches Introduces Brain-Based Strategies for a Healthy Heart 3Health News:B. Eliot Cole, MD, Steps Down as Executive VP at Aventine Healthsciences and Executive Director of American Society of Pain Educators 2Health News:B. Eliot Cole, MD, Steps Down as Executive VP at Aventine Healthsciences and Executive Director of American Society of Pain Educators 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: